Who
ARCH Venture Partners XII, LLC
10% owner
Company insider
Files Form 4 as: 10% owner, City Therapeutics; 10% owner, Seaport Therapeutics; Director and 10% owner, Metsera; 10% owner, Neumora Therapeutics; 10% owner, Prime Medicine.
In numbers
- Trades disclosed
- 21
- Buys
- 7
- Sells
- 0
- Bought
- $49.0M
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 3 Nov 2023
- Last trade
- 19 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Oct 2026filed 19 Oct 2026 | CTY City TherapeuticsBiotechnology | SEC FORM 4 Code C | —3,294,900 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City TherapeuticsBiotechnology | SEC FORM 4 Code C | —5,482,309 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,027,006 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City TherapeuticsBiotechnology | SEC FORM 4 Bought | $3.1M170,000 at $18.00 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,000,000 at $0.00 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —4,991,633 at $0.00 | filing |
| 19 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —1,845,585 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,513,686 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,681,265 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Bought | $19.8M1,100,000 at $18.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,513,686 at $0.00 | filing |
| 4 May 2026filed 4 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —2,681,265 at $0.00 | filing |
| 13 Nov 2025filed 14 Nov 2025 | Metsera | SEC FORM 4 Code D | —18,503,128 | filing |
| 13 Nov 2025filed 14 Nov 2025 | Metsera | SEC FORM 4 Code D | —8,313,680 | filing |
| 27 Oct 2025filed 29 Oct 2025 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.0M1,915,700 at $2.61 | filing |
| 15 Feb 2024filed 20 Feb 2024 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $20.0M3,200,000 at $6.25 | filing |
| 8 Dec 2023filed 12 Dec 2023 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code J | —703,061 | filing |
| 8 Dec 2023filed 12 Dec 2023 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code J | —1,176,593 | filing |
| 7 Nov 2023filed 7 Nov 2023 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Bought | $347K30,192 at $11.50 | filing |
| 6 Nov 2023filed 7 Nov 2023 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Bought | $498K43,082 at $11.55 | filing |
News
No headline names them, or the companies they trade most, lately.